Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
PARIS, Jan. 29, 2016 -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2016.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
| -- 2015 Full-Year Results | March 7, 2016 | |||
| -- Shareholders’ AGM | April 12, 2016 | |||
| -- 2016 Half-Year results | October 14, 2016 |
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
